|
Top Feature
Drug Shortages: Not Going Away Soon
Albert Wertheimer, PhD, MBA, Professor of Pharmaceutical Economics at Temple University and a member of Pharm Exec's Editorial Advisory Board, shows how the simple matter of a drug shortage is not a simple matter at all ...Read more
Value
Can Payers and Industry Agree on Real Value?
In the UK, three years of intensive discussions attempting to quantify the value of prescription drugs through Value-Based Pricing (VBP) have halted abruptly over a rejection of the concept during a public consultation process. Ed Schoonveld wonders where this leave the value debate at large ...Read more
Global
Europe: Putting Off Off-Label Decisions
When in doubt, commission a study. This well-known tactic has come to the rescue of the European Union once again in the face of renewed controversy over off-label prescribing of medicines. EU officials are now pondering who they should nominate to provide a study on the subject, to be completed this year. All of which provides the EU with a perfect excuse for doing nothing in the interim about off-label prescribing, writes Reflector ...Read more
Brand Strategies
"Smart Targeting" and the Growing Influence of IDNs
The growth of provider networks such as integrated delivery networks (IDNs) is one indicator that the barometer of influence is tipping, with physicians no longer the sole gatekeeper of clinical decision-making. IMS Health's John Daly and John Moran talk to PharmExec about the new ways IDNs are impacting the landscape ...Read more
Digital Marketing According to HIPAA
How pharmaceutical companies can break through regulatory constraints to create personal, audience-driven marketing content
 Learn more
Leadership
Deadline for Nomination: Pharm Exec's 2015 Emerging Pharma Leaders
Pharm Exec is looking for the fresh faces of pharma leadership, and we'd like your input! Tell us who you think should be included as one of Pharmaceutical Executive's 2015 Emerging Pharma Leaders. Read more for details of how to nominate a colleague—or yourself. The deadline for this year's entries is April 15
...Read more
Regulatory
Accelerated Change: Understanding the FDA's Expedited Pathways
Jamie Gault outlines the key differentiators between each of FDA's programs to facilitate and expedite drug development and review of new drugs ...Read more
|
